Galecto (GLTO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

GLTO Galecto

Watchlist

5.620
-0.225-3.85%

Close Nov 22 16:00 ET

5.600
-0.020-0.36%

Post 16:47 ET

7.40MMarket Cap-294P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Galecto Anticipates That Its Cash, Cash Equivalents and Investments Will Be Sufficient to Fund Operating Expenses and Cap Requirements for at Least the Next Twelve Mos >GLTO
Dow JonesNov 1 08:31 ET
Galecto Cash, Cash Equivalents, and Investments as of Sept 30 Were $19.7M >GLTO
Dow JonesNov 1 08:31 ET
Express News | Galecto Reports Third Quarter 2024 Financial Results
ReutersNov 1 08:30 ET
Galecto 3Q Loss/Shr $3.39 >GLTO
Dow JonesNov 1 08:30 ET
Galecto 3Q Loss $3.88M >GLTO
Dow JonesNov 1 08:30 ET
Press Release: Galecto Reports Third Quarter 2024 Financial Results
Dow JonesNov 1 08:30 ET

Comments

Jaguar8

Oct 7 08:25

NEWS

$Galecto (GLTO.US)$
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
• Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211
• Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)
• BRM-1420 has the potential for enhanced clinical effectivenes...

Trytosaveabit

Sep 18 05:09

Update

$Galecto (GLTO.US)$ Galecto Has Regained Compliance With The Minimum Bid Price Requirement In Nasdaq Listing Rule

Jaguar8

May 1 15:02

$Galecto (GLTO.US)$
NEWS
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced the enrollment of the first patient in an investigator-initiated Phase 2 trial to evaluate GB1211, a galectin-3 inhibitor, in combination with pembrolizumab for metastatic melanoma and head and neck squamous cell carcinoma. Galecto aims to explore GB1211's potential to enhance the effectiveness of pembrolizumab in various can...